Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma

Doxorubicin (doxo) remains the standard of care for patients with advanced soft tissue sarcoma (STS), even though response rates to doxo are only around 14% to 18%. We evaluated enapotamab vedotin (EnaV), an AXL-specific antibody-drug conjugate (ADC), in a panel of STS patient-derived xenografts (PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Renterghem, Britt, Wozniak, Agnieszka, Castro, Patricia Garrido, Franken, Patrick, Pencheva, Nora, Sciot, Raf, Schöffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322120/
https://www.ncbi.nlm.nih.gov/pubmed/35886842
http://dx.doi.org/10.3390/ijms23147493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322120/
https://www.ncbi.nlm.nih.gov/pubmed/35886842
http://dx.doi.org/10.3390/ijms23147493

Ejemplares similares